The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on ...

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

In a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to ...

British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump ...

On July 21, AstraZeneca said it would invest $50 billion in U.S. production by 2030. At the core is a manufacturing plant to ...

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

U.K.-based drug giant AstraZeneca will make what it calls its single-largest manufacturing investment in the world with a new ...

The biopharmaceutical company AstraZeneca announced it will $50 billion into the United States, with plans to open several ...

UK-based pharmaceutical giant AstraZeneca plans to build its largest drug manufacturing facility in Virginia, creating ...

AstraZeneca's strategic $50B investment promises to revolutionize U.S. medicine production with advanced manufacturing and ...